A NEW formulation of Zytiga (abiraterone acetate) of 500 mg film-coated tablets is now available on the PBS, reducing pill burden for men with metastatic castrate-resistant prostate cancer from four 250mg uncoated pills to two pills per day - see pbs.gov.au.
The drug is an androgen biosynthesis inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy or who have received prior chemotherapy containing a taxane.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 17
